Ernexa Therapeutics Inc. (ERNA) 10-Year Financial Performance & Capital Metrics

ERNA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutErnexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Show more

Revenue $582K +755.9%
EBITDA -$14M +29.9%
Net Income -$45M -105.6%
EPS (Diluted) -1.57 +61.5%
Gross Margin 83.51% +133.8%
EBITDA Margin -2411.68% +91.8%
Operating Margin -2693.13% +91.3%
Net Margin -7652.75% +76.0%
ROE -2264.31% -649.3%
ROIC -63.27% +17.6%
Debt/Equity 0.40 -97.9%
Interest Coverage -2.32 +93.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 13 (bottom 13%)
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 50.6% over 5 years
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-50.61%

3Y-

TTM-99.83%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM59.18%

EPS CAGR

10Y-

5Y-

3Y-

TTM84%

ROCE

10Y Avg-108.18%

5Y Avg-196.22%

3Y Avg-100.06%

Latest-69.83%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	24.52M	22.31M	21.27M	23.34M	19.81M	0	0	0	68K	582K
Revenue Growth %	-	-0.09%	-0.05%	0.1%	-0.15%	-1%	-	-	-	7.56%
Cost of Goods Sold+	13.06M	8.13M	7.09M	8.38M	7.84M	98K	0	0	236K	96K
COGS % of Revenue	0.53%	0.36%	0.33%	0.36%	0.4%	-	-	-	3.47%	0.16%
Gross Profit+	11.46M	14.18M	14.19M	14.95M	11.96M	-98K	0	0	-168K	486K
Gross Margin %	0.47%	0.64%	0.67%	0.64%	0.6%	-	-	-	-2.47%	0.84%
Gross Profit Growth %	-	0.24%	0%	0.05%	-0.2%	-1.01%	1%	-	-	3.89%
Operating Expenses+	18.06M	16.46M	15.59M	14.49M	13.18M	7.15M	113.73M	33.22M	20.97M	16.16M
OpEx % of Revenue	0.74%	0.74%	0.73%	0.62%	0.67%	-	-	-	308.34%	27.77%
Selling, General & Admin	18.06M	16.46M	15.45M	14.41M	13.15M	3.3M	14.72M	16.55M	14.59M	13.13M
SG&A % of Revenue	0.74%	0.74%	0.73%	0.62%	0.66%	-	-	-	214.5%	22.56%
Research & Development	0	0	139K	72K	26K	3.95M	12.71M	10.39M	5.92M	4.6M
R&D % of Revenue	-	-	0.01%	0%	0%	-	-	-	87.06%	7.91%
Other Operating Expenses	0	0	0	0	0	-98K	86.3M	6.27M	461K	-1.58M
Operating Income+	-6.6M	-2.28M	-1.4M	464K	-1.21M	-7.25M	-113.73M	-33.22M	-21.14M	-15.67M
Operating Margin %	-0.27%	-0.1%	-0.07%	0.02%	-0.06%	-	-	-	-310.81%	-26.93%
Operating Income Growth %	-	0.65%	0.38%	1.33%	-3.61%	-4.98%	-14.69%	0.71%	0.36%	0.26%
EBITDA+	-3.5M	609K	915K	3.23M	1.96M	-7.15M	-113.27M	-32.72M	-20.01M	-14.04M
EBITDA Margin %	-0.14%	0.03%	0.04%	0.14%	0.1%	-	-	-	-294.29%	-24.12%
EBITDA Growth %	-	1.17%	0.5%	2.53%	-0.39%	-4.66%	-14.84%	0.71%	0.39%	0.3%
D&A (Non-Cash Add-back)	3.1M	2.89M	2.32M	2.76M	3.17M	98K	459K	497K	1.12M	1.64M
EBIT	-6.73M	-2.31M	-513K	66K	-1.77M	-26.49M	-122.41M	-24.5M	-21.06M	-37.76M
Net Interest Income+	-481K	0	0	0	-249K	-43K	-74K	-30K	-476K	-6.5M
Interest Income	3K	0	0	0	-	0	0	0	138K	249K
Interest Expense	484K	576K	498K	389K	249K	43K	74K	30K	614K	6.75M
Other Income/Expense	-614K	-607K	391K	-787K	-808K	-19.28M	-8.75M	8.68M	-536K	-28.84M
Pretax Income+	-7.21M	-2.88M	-1.01M	-323K	-2.02M	-26.53M	-122.48M	-24.53M	-21.67M	-44.51M
Pretax Margin %	-0.29%	-0.13%	-0.05%	-0.01%	-0.1%	-	-	-	-318.69%	-76.48%
Income Tax+	12K	38K	66K	-64K	27K	0	64K	45K	-3K	30K
Effective Tax Rate %	1%	1.01%	1.07%	0.8%	1.01%	-0.45%	1%	1%	1%	1%
Net Income+	-7.23M	-2.92M	-1.08M	-259K	-2.05M	11.91M	-122.55M	-24.58M	-21.67M	-44.54M
Net Margin %	-0.29%	-0.13%	-0.05%	-0.01%	-0.1%	-	-	-	-318.65%	-76.53%
Net Income Growth %	-	0.6%	0.63%	0.76%	-6.9%	6.82%	-11.29%	0.8%	0.12%	-1.06%
Net Income (Continuing)	-7.23M	-2.92M	-1.08M	-259K	-2.05M	-26.53M	-122.55M	-24.58M	-21.67M	-44.54M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-157.26	-61.44	-17.64	-3.85	-28.48	-3.51	-56.61	-8.06	-4.08	-1.57
EPS Growth %	-	0.61%	0.71%	0.78%	-6.4%	0.88%	-15.13%	0.86%	0.49%	0.62%
EPS (Basic)	-157.26	-61.44	-17.64	-3.85	-28.48	-3.51	-56.61	-8.06	-4.08	-1.57
Diluted Shares Outstanding	45.95K	47.58K	61.05K	67.2K	71.88K	1.73M	2.17M	3.05M	5.31M	28.4M
Basic Shares Outstanding	45.95K	47.58K	61.05K	67.2K	71.88K	1.73M	2.17M	3.05M	5.31M	28.4M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.11M	10.66M	9.64M	6.79M	6.07M	1.73M	18.77M	13.68M	9.6M	2.35M
Cash & Short-Term Investments	3.22M	5.69M	3.38M	2.59M	3.26M	1.63M	16.98M	11.45M	7.58M	1.73M
Cash Only	3.22M	5.69M	3.38M	2.59M	3.26M	1.63M	16.98M	11.45M	7.58M	1.73M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	919K	928K	714K	1.14M	1.2M	0	684K	951K	425K	437K
Days Sales Outstanding	13.68	15.18	12.25	17.88	22.02	-	-	-	2.28K	274.06
Inventory	0	3M	4.87M	2.54M	1.09M	0	0	0	0	0
Days Inventory Outstanding	-	134.56	250.54	110.52	50.73	-	-	-	-	-
Other Current Assets	4.97M	1.05M	680K	517K	526K	0	0	0	1.6M	186K
Total Non-Current Assets+	7.71M	6.47M	6.93M	8.08M	9.21M	11.17M	12.76M	8.6M	39.53M	2.92M
Property, Plant & Equipment	3.92M	3.1M	3.68M	4.67M	4.92M	2.69M	3.24M	1.27M	33.27M	755K
Fixed Asset Turnover	6.26x	7.20x	5.78x	5.00x	4.02x	-	-	-	0.00x	0.77x
Goodwill	909K	937K	1M	667K	696K	2.04M	2.04M	2.04M	2.04M	2.04M
Intangible Assets	0	0	0	0	1.92M	5.99M	5.99M	0	0	0
Long-Term Investments	1.02M	999K	1.09M	200K	150K	-449K	1M	59K	0	0
Other Non-Current Assets	1.45M	984K	791K	527K	371K	453K	488K	5.23M	4.21M	118K
Total Assets+	16.82M	17.14M	16.57M	14.86M	15.28M	12.91M	31.52M	22.28M	49.13M	5.27M
Asset Turnover	1.46x	1.30x	1.28x	1.57x	1.30x	-	-	-	0.00x	0.11x
Asset Growth %	-	0.02%	-0.03%	-0.1%	0.03%	-0.16%	1.44%	-0.29%	1.21%	-0.89%
Total Current Liabilities+	5.12M	6.64M	10.75M	4.02M	6.09M	3.13M	3.68M	7.65M	6.57M	2.94M
Accounts Payable	211K	247K	390K	271K	835K	1.27M	1.75M	1.62M	1.07M	1.72M
Days Payables Outstanding	5.9	11.09	20.08	11.8	38.86	4.75K	-	-	1.65K	6.54K
Short-Term Debt	1.15M	3.14M	5.24M	1.04M	3.17M	526K	0	1.75M	0	207K
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	460K	76K	0	0	190K	0
Other Current Liabilities	2.55M	2.19M	1.56M	1.34M	1.04M	681K	903K	-322K	109K	12K
Current Ratio	1.78x	1.60x	0.90x	1.69x	1.00x	0.55x	5.10x	1.79x	1.46x	0.80x
Quick Ratio	1.78x	1.15x	0.44x	1.06x	0.82x	0.55x	5.10x	1.79x	1.46x	0.80x
Cash Conversion Cycle	-	138.66	242.71	116.6	33.89	-	-	-	-	-
Total Non-Current Liabilities+	7.85M	6.42M	287K	3.92M	4.09M	2.12M	2.34M	2.52M	40.33M	630K
Long-Term Debt	6.37M	5.12M	8K	2.73M	0	194K	0	1.21M	6.77M	0
Capital Lease Obligations	138K	259K	0	41K	2.91M	1.91M	2.3M	887K	32.85M	477K
Deferred Tax Liabilities	415K	441K	424K	41K	1.13M	0	0	0	0	0
Other Non-Current Liabilities	541K	383K	-208K	1.08M	44K	23K	47K	425K	307K	153K
Total Liabilities	12.97M	13.07M	11.03M	7.95M	10.19M	5.25M	6.02M	10.17M	46.9M	3.57M
Total Debt+	7.65M	8.53M	5.41M	3.81M	6.08M	2.9M	2.72M	4.14M	41.84M	684K
Net Debt	4.43M	2.84M	2.03M	1.23M	2.82M	1.27M	-14.26M	-7.31M	34.27M	-1.04M
Debt / Equity	1.99x	2.10x	0.98x	0.55x	1.19x	0.38x	0.11x	0.34x	18.74x	0.40x
Debt / EBITDA	-	14.00x	5.91x	1.18x	3.11x	-	-	-	-	-
Net Debt / EBITDA	-	4.66x	2.22x	0.38x	1.44x	-	-	-	-	-
Interest Coverage	-13.64x	-3.95x	-2.82x	1.19x	-4.87x	-168.56x	-1536.92x	-1107.23x	-34.42x	-2.32x
Total Equity+	3.85M	4.07M	5.54M	6.92M	5.09M	7.66M	25.5M	12.11M	2.23M	1.7M
Equity Growth %	-	0.06%	0.36%	0.25%	-0.26%	0.5%	2.33%	-0.53%	-0.82%	-0.24%
Book Value per Share	83.75	85.51	90.68	102.93	70.83	4.42	11.78	3.97	0.42	0.06
Total Shareholders' Equity	3.85M	4.07M	5.54M	6.92M	5.09M	7.66M	25.5M	12.11M	2.23M	1.7M
Common Stock	462K	11K	13K	14K	14K	25.8M	13K	26K	27K	257K
Retained Earnings	-125.09M	-128.03M	-129.12M	-129.39M	-131.46M	-18.14M	-140.7M	-165.3M	-186.98M	-231.54M
Treasury Stock	-456K	-456K	-456K	-456K	-456K	0	0	0	0	0
Accumulated OCI	172K	223K	345K	200K	268K	245K	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.18M	23K	549K	1.36M	2.74M	-8.1M	-23.49M	-20.98M	-20.41M	-15.84M
Operating CF Margin %	-0.17%	0%	0.03%	0.06%	0.14%	-	-	-	-300.12%	-27.21%
Operating CF Growth %	-	1.01%	22.87%	1.49%	1.01%	-3.95%	-1.9%	0.11%	0.03%	0.22%
Net Income	-7.23M	-2.92M	-1.08M	-259K	-2.05M	-26.53M	-122.55M	-24.58M	-21.67M	-44.54M
Depreciation & Amortization	3.1M	2.89M	2.32M	2.76M	3.17M	98K	459K	497K	1.12M	1.64M
Stock-Based Compensation	0	0	0	0	0	0	5.24M	2.94M	1.24M	1.52M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	6.94M	6.66M	10.05M	6.92M	1.66M	19.33M	95.65M	-3.54M	1.01M	27.52M
Working Capital Changes	-1.67M	-571K	-1.73M	-2.27M	-37K	-999K	-2.29M	3.71M	-2.12M	-1.98M
Change in Receivables	1.25M	-83K	142K	-507K	-248K	0	-659K	-262K	527K	-12K
Change in Inventory	0	-217K	-3.93M	431K	337K	52K	0	0	0	0
Change in Payables	-372K	47K	-586K	-186K	669K	-1.73M	-485K	2.03M	-2.9M	183K
Cash from Investing+	-1.62M	-840K	-1.45M	-1.58M	-1.06M	-39K	-22.74M	-47K	-19K	-365K
Capital Expenditures	-1.63M	-840K	-1.45M	-1.61M	-1.09M	-39K	-154K	-297K	-19K	-369K
CapEx % of Revenue	0.07%	0.04%	0.07%	0.07%	0.06%	-	-	-	0.28%	0.63%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	119K	250K	0	4K
Cash from Financing+	1.98M	3.26M	-1.47M	-303K	-1.1M	4.67M	61.59M	19.58M	16.56M	6.26M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-16K	-16K	-16K	-16K	0	-8K	-16K	-16K	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.98M	-3K	0	-17K	-1.08M	0	10K	-109K	-251K	-169K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.81M	-817K	-903K	-247K	1.65M	-8.14M	-23.64M	-21.27M	-20.43M	-16.2M
FCF Margin %	-0.24%	-0.04%	-0.04%	-0.01%	0.08%	-	-	-	-300.4%	-27.84%
FCF Growth %	-	0.86%	-0.11%	0.73%	7.68%	-5.93%	-1.9%	0.1%	0.04%	0.21%
FCF per Share	-126.49	-17.17	-14.79	-3.68	22.96	-4.70	-10.92	-6.97	-3.84	-0.57
FCF Conversion (FCF/Net Income)	0.58x	-0.01x	-0.51x	-5.27x	-1.34x	-0.68x	0.19x	0.85x	0.94x	0.36x
Interest Paid	0	0	0	0	0	0	225K	30K	20K	48K
Taxes Paid	0	0	0	0	0	0	1K	15K	4K	2K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-187.79%	-73.85%	-22.43%	-4.16%	-34.09%	186.76%	-739.05%	-130.7%	-302.2%	-2264.31%
Return on Invested Capital (ROIC)	-59.79%	-22.5%	-14.53%	4.43%	-11.32%	-64.56%	-845.84%	-310.61%	-76.76%	-63.27%
Gross Margin	46.74%	63.55%	66.68%	64.07%	60.4%	-	-	-	-247.06%	83.51%
Net Margin	-29.47%	-13.1%	-5.06%	-1.11%	-10.34%	-	-	-	-31864.71%	-7652.75%
Debt / Equity	1.99x	2.10x	0.98x	0.55x	1.19x	0.38x	0.11x	0.34x	18.74x	0.40x
Interest Coverage	-13.64x	-3.95x	-2.82x	1.19x	-4.87x	-168.56x	-1536.92x	-1107.23x	-34.42x	-2.32x
FCF Conversion	0.58x	-0.01x	-0.51x	-5.27x	-1.34x	-0.68x	0.19x	0.85x	0.94x	0.36x
Revenue Growth	-	-9%	-4.65%	9.69%	-15.12%	-100%	-	-	-	755.88%

Frequently Asked Questions

Growth & Financials

Ernexa Therapeutics Inc. (ERNA) reported $0.0M in revenue for fiscal year 2024. This represents a 100% decrease from $24.5M in 2015.

Ernexa Therapeutics Inc. (ERNA) grew revenue by 755.9% over the past year. This is strong growth.

Ernexa Therapeutics Inc. (ERNA) reported a net loss of $18.3M for fiscal year 2024.

Dividend & Returns

Ernexa Therapeutics Inc. (ERNA) has a return on equity (ROE) of -2264.3%. Negative ROE indicates the company is unprofitable.

Ernexa Therapeutics Inc. (ERNA) had negative free cash flow of $9.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Ernexa Therapeutics Inc. (ERNA) 10-Year Financial Performance & Capital Metrics

ERNA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $582K +755.9%
EBITDA -$14M +29.9%
Net Income -$45M -105.6%
EPS (Diluted) -1.57 +61.5%
Gross Margin 83.51% +133.8%
EBITDA Margin -2411.68% +91.8%
Operating Margin -2693.13% +91.3%
Net Margin -7652.75% +76.0%
ROE -2264.31% -649.3%
ROIC -63.27% +17.6%
Debt/Equity 0.40 -97.9%
Interest Coverage -2.32 +93.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 13 (bottom 13%)
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 50.6% over 5 years
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-50.61%

3Y-

TTM-99.83%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM59.18%

EPS CAGR

10Y-

5Y-

3Y-

TTM84%

ROCE

10Y Avg-108.18%

5Y Avg-196.22%

3Y Avg-100.06%

Latest-69.83%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	24.52M	22.31M	21.27M	23.34M	19.81M	0	0	0	68K	582K
Revenue Growth %	-	-0.09%	-0.05%	0.1%	-0.15%	-1%	-	-	-	7.56%
Cost of Goods Sold+	13.06M	8.13M	7.09M	8.38M	7.84M	98K	0	0	236K	96K
COGS % of Revenue	0.53%	0.36%	0.33%	0.36%	0.4%	-	-	-	3.47%	0.16%
Gross Profit+	11.46M	14.18M	14.19M	14.95M	11.96M	-98K	0	0	-168K	486K
Gross Margin %	0.47%	0.64%	0.67%	0.64%	0.6%	-	-	-	-2.47%	0.84%
Gross Profit Growth %	-	0.24%	0%	0.05%	-0.2%	-1.01%	1%	-	-	3.89%
Operating Expenses+	18.06M	16.46M	15.59M	14.49M	13.18M	7.15M	113.73M	33.22M	20.97M	16.16M
OpEx % of Revenue	0.74%	0.74%	0.73%	0.62%	0.67%	-	-	-	308.34%	27.77%
Selling, General & Admin	18.06M	16.46M	15.45M	14.41M	13.15M	3.3M	14.72M	16.55M	14.59M	13.13M
SG&A % of Revenue	0.74%	0.74%	0.73%	0.62%	0.66%	-	-	-	214.5%	22.56%
Research & Development	0	0	139K	72K	26K	3.95M	12.71M	10.39M	5.92M	4.6M
R&D % of Revenue	-	-	0.01%	0%	0%	-	-	-	87.06%	7.91%
Other Operating Expenses	0	0	0	0	0	-98K	86.3M	6.27M	461K	-1.58M
Operating Income+	-6.6M	-2.28M	-1.4M	464K	-1.21M	-7.25M	-113.73M	-33.22M	-21.14M	-15.67M
Operating Margin %	-0.27%	-0.1%	-0.07%	0.02%	-0.06%	-	-	-	-310.81%	-26.93%
Operating Income Growth %	-	0.65%	0.38%	1.33%	-3.61%	-4.98%	-14.69%	0.71%	0.36%	0.26%
EBITDA+	-3.5M	609K	915K	3.23M	1.96M	-7.15M	-113.27M	-32.72M	-20.01M	-14.04M
EBITDA Margin %	-0.14%	0.03%	0.04%	0.14%	0.1%	-	-	-	-294.29%	-24.12%
EBITDA Growth %	-	1.17%	0.5%	2.53%	-0.39%	-4.66%	-14.84%	0.71%	0.39%	0.3%
D&A (Non-Cash Add-back)	3.1M	2.89M	2.32M	2.76M	3.17M	98K	459K	497K	1.12M	1.64M
EBIT	-6.73M	-2.31M	-513K	66K	-1.77M	-26.49M	-122.41M	-24.5M	-21.06M	-37.76M
Net Interest Income+	-481K	0	0	0	-249K	-43K	-74K	-30K	-476K	-6.5M
Interest Income	3K	0	0	0	-	0	0	0	138K	249K
Interest Expense	484K	576K	498K	389K	249K	43K	74K	30K	614K	6.75M
Other Income/Expense	-614K	-607K	391K	-787K	-808K	-19.28M	-8.75M	8.68M	-536K	-28.84M
Pretax Income+	-7.21M	-2.88M	-1.01M	-323K	-2.02M	-26.53M	-122.48M	-24.53M	-21.67M	-44.51M
Pretax Margin %	-0.29%	-0.13%	-0.05%	-0.01%	-0.1%	-	-	-	-318.69%	-76.48%
Income Tax+	12K	38K	66K	-64K	27K	0	64K	45K	-3K	30K
Effective Tax Rate %	1%	1.01%	1.07%	0.8%	1.01%	-0.45%	1%	1%	1%	1%
Net Income+	-7.23M	-2.92M	-1.08M	-259K	-2.05M	11.91M	-122.55M	-24.58M	-21.67M	-44.54M
Net Margin %	-0.29%	-0.13%	-0.05%	-0.01%	-0.1%	-	-	-	-318.65%	-76.53%
Net Income Growth %	-	0.6%	0.63%	0.76%	-6.9%	6.82%	-11.29%	0.8%	0.12%	-1.06%
Net Income (Continuing)	-7.23M	-2.92M	-1.08M	-259K	-2.05M	-26.53M	-122.55M	-24.58M	-21.67M	-44.54M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-157.26	-61.44	-17.64	-3.85	-28.48	-3.51	-56.61	-8.06	-4.08	-1.57
EPS Growth %	-	0.61%	0.71%	0.78%	-6.4%	0.88%	-15.13%	0.86%	0.49%	0.62%
EPS (Basic)	-157.26	-61.44	-17.64	-3.85	-28.48	-3.51	-56.61	-8.06	-4.08	-1.57
Diluted Shares Outstanding	45.95K	47.58K	61.05K	67.2K	71.88K	1.73M	2.17M	3.05M	5.31M	28.4M
Basic Shares Outstanding	45.95K	47.58K	61.05K	67.2K	71.88K	1.73M	2.17M	3.05M	5.31M	28.4M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.11M	10.66M	9.64M	6.79M	6.07M	1.73M	18.77M	13.68M	9.6M	2.35M
Cash & Short-Term Investments	3.22M	5.69M	3.38M	2.59M	3.26M	1.63M	16.98M	11.45M	7.58M	1.73M
Cash Only	3.22M	5.69M	3.38M	2.59M	3.26M	1.63M	16.98M	11.45M	7.58M	1.73M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	919K	928K	714K	1.14M	1.2M	0	684K	951K	425K	437K
Days Sales Outstanding	13.68	15.18	12.25	17.88	22.02	-	-	-	2.28K	274.06
Inventory	0	3M	4.87M	2.54M	1.09M	0	0	0	0	0
Days Inventory Outstanding	-	134.56	250.54	110.52	50.73	-	-	-	-	-
Other Current Assets	4.97M	1.05M	680K	517K	526K	0	0	0	1.6M	186K
Total Non-Current Assets+	7.71M	6.47M	6.93M	8.08M	9.21M	11.17M	12.76M	8.6M	39.53M	2.92M
Property, Plant & Equipment	3.92M	3.1M	3.68M	4.67M	4.92M	2.69M	3.24M	1.27M	33.27M	755K
Fixed Asset Turnover	6.26x	7.20x	5.78x	5.00x	4.02x	-	-	-	0.00x	0.77x
Goodwill	909K	937K	1M	667K	696K	2.04M	2.04M	2.04M	2.04M	2.04M
Intangible Assets	0	0	0	0	1.92M	5.99M	5.99M	0	0	0
Long-Term Investments	1.02M	999K	1.09M	200K	150K	-449K	1M	59K	0	0
Other Non-Current Assets	1.45M	984K	791K	527K	371K	453K	488K	5.23M	4.21M	118K
Total Assets+	16.82M	17.14M	16.57M	14.86M	15.28M	12.91M	31.52M	22.28M	49.13M	5.27M
Asset Turnover	1.46x	1.30x	1.28x	1.57x	1.30x	-	-	-	0.00x	0.11x
Asset Growth %	-	0.02%	-0.03%	-0.1%	0.03%	-0.16%	1.44%	-0.29%	1.21%	-0.89%
Total Current Liabilities+	5.12M	6.64M	10.75M	4.02M	6.09M	3.13M	3.68M	7.65M	6.57M	2.94M
Accounts Payable	211K	247K	390K	271K	835K	1.27M	1.75M	1.62M	1.07M	1.72M
Days Payables Outstanding	5.9	11.09	20.08	11.8	38.86	4.75K	-	-	1.65K	6.54K
Short-Term Debt	1.15M	3.14M	5.24M	1.04M	3.17M	526K	0	1.75M	0	207K
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	460K	76K	0	0	190K	0
Other Current Liabilities	2.55M	2.19M	1.56M	1.34M	1.04M	681K	903K	-322K	109K	12K
Current Ratio	1.78x	1.60x	0.90x	1.69x	1.00x	0.55x	5.10x	1.79x	1.46x	0.80x
Quick Ratio	1.78x	1.15x	0.44x	1.06x	0.82x	0.55x	5.10x	1.79x	1.46x	0.80x
Cash Conversion Cycle	-	138.66	242.71	116.6	33.89	-	-	-	-	-
Total Non-Current Liabilities+	7.85M	6.42M	287K	3.92M	4.09M	2.12M	2.34M	2.52M	40.33M	630K
Long-Term Debt	6.37M	5.12M	8K	2.73M	0	194K	0	1.21M	6.77M	0
Capital Lease Obligations	138K	259K	0	41K	2.91M	1.91M	2.3M	887K	32.85M	477K
Deferred Tax Liabilities	415K	441K	424K	41K	1.13M	0	0	0	0	0
Other Non-Current Liabilities	541K	383K	-208K	1.08M	44K	23K	47K	425K	307K	153K
Total Liabilities	12.97M	13.07M	11.03M	7.95M	10.19M	5.25M	6.02M	10.17M	46.9M	3.57M
Total Debt+	7.65M	8.53M	5.41M	3.81M	6.08M	2.9M	2.72M	4.14M	41.84M	684K
Net Debt	4.43M	2.84M	2.03M	1.23M	2.82M	1.27M	-14.26M	-7.31M	34.27M	-1.04M
Debt / Equity	1.99x	2.10x	0.98x	0.55x	1.19x	0.38x	0.11x	0.34x	18.74x	0.40x
Debt / EBITDA	-	14.00x	5.91x	1.18x	3.11x	-	-	-	-	-
Net Debt / EBITDA	-	4.66x	2.22x	0.38x	1.44x	-	-	-	-	-
Interest Coverage	-13.64x	-3.95x	-2.82x	1.19x	-4.87x	-168.56x	-1536.92x	-1107.23x	-34.42x	-2.32x
Total Equity+	3.85M	4.07M	5.54M	6.92M	5.09M	7.66M	25.5M	12.11M	2.23M	1.7M
Equity Growth %	-	0.06%	0.36%	0.25%	-0.26%	0.5%	2.33%	-0.53%	-0.82%	-0.24%
Book Value per Share	83.75	85.51	90.68	102.93	70.83	4.42	11.78	3.97	0.42	0.06
Total Shareholders' Equity	3.85M	4.07M	5.54M	6.92M	5.09M	7.66M	25.5M	12.11M	2.23M	1.7M
Common Stock	462K	11K	13K	14K	14K	25.8M	13K	26K	27K	257K
Retained Earnings	-125.09M	-128.03M	-129.12M	-129.39M	-131.46M	-18.14M	-140.7M	-165.3M	-186.98M	-231.54M
Treasury Stock	-456K	-456K	-456K	-456K	-456K	0	0	0	0	0
Accumulated OCI	172K	223K	345K	200K	268K	245K	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.18M	23K	549K	1.36M	2.74M	-8.1M	-23.49M	-20.98M	-20.41M	-15.84M
Operating CF Margin %	-0.17%	0%	0.03%	0.06%	0.14%	-	-	-	-300.12%	-27.21%
Operating CF Growth %	-	1.01%	22.87%	1.49%	1.01%	-3.95%	-1.9%	0.11%	0.03%	0.22%
Net Income	-7.23M	-2.92M	-1.08M	-259K	-2.05M	-26.53M	-122.55M	-24.58M	-21.67M	-44.54M
Depreciation & Amortization	3.1M	2.89M	2.32M	2.76M	3.17M	98K	459K	497K	1.12M	1.64M
Stock-Based Compensation	0	0	0	0	0	0	5.24M	2.94M	1.24M	1.52M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	6.94M	6.66M	10.05M	6.92M	1.66M	19.33M	95.65M	-3.54M	1.01M	27.52M
Working Capital Changes	-1.67M	-571K	-1.73M	-2.27M	-37K	-999K	-2.29M	3.71M	-2.12M	-1.98M
Change in Receivables	1.25M	-83K	142K	-507K	-248K	0	-659K	-262K	527K	-12K
Change in Inventory	0	-217K	-3.93M	431K	337K	52K	0	0	0	0
Change in Payables	-372K	47K	-586K	-186K	669K	-1.73M	-485K	2.03M	-2.9M	183K
Cash from Investing+	-1.62M	-840K	-1.45M	-1.58M	-1.06M	-39K	-22.74M	-47K	-19K	-365K
Capital Expenditures	-1.63M	-840K	-1.45M	-1.61M	-1.09M	-39K	-154K	-297K	-19K	-369K
CapEx % of Revenue	0.07%	0.04%	0.07%	0.07%	0.06%	-	-	-	0.28%	0.63%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	119K	250K	0	4K
Cash from Financing+	1.98M	3.26M	-1.47M	-303K	-1.1M	4.67M	61.59M	19.58M	16.56M	6.26M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-16K	-16K	-16K	-16K	0	-8K	-16K	-16K	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.98M	-3K	0	-17K	-1.08M	0	10K	-109K	-251K	-169K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.81M	-817K	-903K	-247K	1.65M	-8.14M	-23.64M	-21.27M	-20.43M	-16.2M
FCF Margin %	-0.24%	-0.04%	-0.04%	-0.01%	0.08%	-	-	-	-300.4%	-27.84%
FCF Growth %	-	0.86%	-0.11%	0.73%	7.68%	-5.93%	-1.9%	0.1%	0.04%	0.21%
FCF per Share	-126.49	-17.17	-14.79	-3.68	22.96	-4.70	-10.92	-6.97	-3.84	-0.57
FCF Conversion (FCF/Net Income)	0.58x	-0.01x	-0.51x	-5.27x	-1.34x	-0.68x	0.19x	0.85x	0.94x	0.36x
Interest Paid	0	0	0	0	0	0	225K	30K	20K	48K
Taxes Paid	0	0	0	0	0	0	1K	15K	4K	2K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-187.79%	-73.85%	-22.43%	-4.16%	-34.09%	186.76%	-739.05%	-130.7%	-302.2%	-2264.31%
Return on Invested Capital (ROIC)	-59.79%	-22.5%	-14.53%	4.43%	-11.32%	-64.56%	-845.84%	-310.61%	-76.76%	-63.27%
Gross Margin	46.74%	63.55%	66.68%	64.07%	60.4%	-	-	-	-247.06%	83.51%
Net Margin	-29.47%	-13.1%	-5.06%	-1.11%	-10.34%	-	-	-	-31864.71%	-7652.75%
Debt / Equity	1.99x	2.10x	0.98x	0.55x	1.19x	0.38x	0.11x	0.34x	18.74x	0.40x
Interest Coverage	-13.64x	-3.95x	-2.82x	1.19x	-4.87x	-168.56x	-1536.92x	-1107.23x	-34.42x	-2.32x
FCF Conversion	0.58x	-0.01x	-0.51x	-5.27x	-1.34x	-0.68x	0.19x	0.85x	0.94x	0.36x
Revenue Growth	-	-9%	-4.65%	9.69%	-15.12%	-100%	-	-	-	755.88%

Frequently Asked Questions

Growth & Financials

Ernexa Therapeutics Inc. (ERNA) reported $0.0M in revenue for fiscal year 2024. This represents a 100% decrease from $24.5M in 2015.

Ernexa Therapeutics Inc. (ERNA) grew revenue by 755.9% over the past year. This is strong growth.

Ernexa Therapeutics Inc. (ERNA) reported a net loss of $18.3M for fiscal year 2024.

Dividend & Returns

Ernexa Therapeutics Inc. (ERNA) has a return on equity (ROE) of -2264.3%. Negative ROE indicates the company is unprofitable.

Ernexa Therapeutics Inc. (ERNA) had negative free cash flow of $9.4M in fiscal year 2024, likely due to heavy capital investments.